NASDAQ · AGIO
Healthcare · Biotechnology
$32.58
Down-$0.32 (-0.97%)
Updated Sep 26, 2026, 5:04 PM
SID Score
4.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
AGIO closed at $32.58 after 20 trading sessions, down 2.22% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 25, 2026 | $32.93 | $33.33 | $32.54 | $32.58 | 996.51K |
| Sep 24, 2026 | $34.02 | $34.125 | $31.37 | $32.90 | 1.64M |
| Sep 23, 2026 | $34.85 | $35.09 | $34.09 | $34.19 | 752.48K |
| Sep 22, 2026 | $34.19 | $35.36 | $33.875 | $34.97 | 1.17M |
| Sep 21, 2026 | $33.70 | $34.135 | $33.30 | $33.95 | 884.55K |
| Sep 18, 2026 | $33.29 | $33.3999 | $32.77 | $33.07 | 1.57M |
| Sep 17, 2026 | $33.42 | $34.295 | $33.19 | $33.61 | 956.68K |
| Sep 16, 2026 | $32.89 | $33.75 | $32.735 | $32.95 | 863.62K |
| Sep 15, 2026 | $33.23 | $33.48 | $32.215 | $32.81 | 1.35M |
| Sep 14, 2026 | $33.83 | $34.355 | $32.885 | $33.22 | 794.48K |
| Sep 11, 2026 | $33.94 | $34.28 | $33.32 | $33.60 | 750.17K |
| Sep 10, 2026 | $34.26 | $35.28 | $33.21 | $33.64 | 720.26K |
| Sep 9, 2026 | $33.14 | $35.375 | $33.14 | $34.63 | 1.02M |
| Sep 8, 2026 | $32.53 | $33.93 | $32.23 | $33.55 | 816.36K |
| Sep 4, 2026 | $33.13 | $33.50 | $32.92 | $33.10 | 480.16K |
| Sep 3, 2026 | $34.28 | $34.39 | $32.95 | $33.13 | 516.04K |
| Sep 2, 2026 | $34.49 | $34.93 | $33.535 | $34.13 | 771.68K |
| Sep 1, 2026 | $33.60 | $34.34 | $33.21 | $34.21 | 926.96K |
| Aug 31, 2026 | $33.09 | $33.865 | $32.9275 | $33.68 | 1.11M |
| Aug 28, 2026 | $33.94 | $34.36 | $33.27 | $33.32 | 519.74K |
The latest Smart Investors Daily articles mentioning AGIO.
AGIO research
Company profile and research snapshot.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 21, 2026 | B of A Securities | Buy | — |
| Aug 7, 2026 | JP Morgan | Neutral | — |
| Jul 31, 2026 | Citigroup | Buy | — |
| Jul 31, 2026 | Truist Securities | Buy | — |
| Jul 30, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Sep 21, 2026
B of A Securities analyst Alec Stranahan maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and raises the price target from $46 to $50.
SeekingAlpha · Aug 20, 2026
Agios is leveraging mitapivat across PK deficiency, thalassemia, and sickle cell disease to build a rare disease franchise. Read more on AGIO stock here.
Benzinga · Aug 7, 2026
JP Morgan analyst Tessa Romero maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Neutral and raises the price target from $31 to $34.
Benzinga · Jul 31, 2026
Citigroup analyst Samantha Semenkow maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and raises the price target from $46 to $52.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning AGIO.
